FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2049402010> ?p ?o ?g. }

• W2049402010 endingPage "849.e1" @default.
• W2049402010 startingPage "840" @default.
• W2049402010 abstract "Background & AimsInterferon reportedly decreases the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C. The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial showed that 4 years of maintenance therapy with pegylated interferon (peginterferon) does not reduce liver disease progression. We investigated whether peginterferon decreases the incidence of HCC in the HALT-C cohort over a longer posttreatment follow-up period.MethodsThe study included 1048 patients with chronic hepatitis C (Ishak fibrosis scores ≥3) who did not have a sustained virologic response (SVR) to therapy. They were randomly assigned to groups given a half-dose of peginterferon or no treatment (controls) for 3.5 years and followed up for a median of 6.1 (maximum, 8.7) years.ResultsEighty-eight patients developed HCC (68 definite, 20 presumed): 37 of 515 who were given peginterferon (7.2%) and 51 of 533 controls (9.6%; P = .24). There was a significantly lower incidence of HCC among patients given peginterferon therapy who had cirrhosis, but not fibrosis, based on analysis of baseline biopsy samples. After 7 years, the cumulative incidences of HCC in treated and control patients with cirrhosis were 7.8% and 24.2%, respectively (hazard ratio [HR], 0.45; 95% confidence interval [CI], 0.24–0.83); in treated and control patients with fibrosis, incidences were 8.3% and 6.8%, respectively (HR, 1.44; 95% CI, 0.77–2.69). Treated patients with a ≥2-point decrease in the histologic activity index, based on a follow-up biopsy, had a lower incidence of HCC than those with unchanged or increased scores (2.9% vs 9.4%; P = .03).ConclusionsExtended analysis of the HALT-C cohort showed that long-term peginterferon therapy does not reduce the incidence of HCC among patients with advanced hepatitis C who did not achieve SVRs. Patients with cirrhosis who received peginterferon treatment had a lower risk of HCC than controls. Interferon reportedly decreases the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C. The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial showed that 4 years of maintenance therapy with pegylated interferon (peginterferon) does not reduce liver disease progression. We investigated whether peginterferon decreases the incidence of HCC in the HALT-C cohort over a longer posttreatment follow-up period. The study included 1048 patients with chronic hepatitis C (Ishak fibrosis scores ≥3) who did not have a sustained virologic response (SVR) to therapy. They were randomly assigned to groups given a half-dose of peginterferon or no treatment (controls) for 3.5 years and followed up for a median of 6.1 (maximum, 8.7) years. Eighty-eight patients developed HCC (68 definite, 20 presumed): 37 of 515 who were given peginterferon (7.2%) and 51 of 533 controls (9.6%; P = .24). There was a significantly lower incidence of HCC among patients given peginterferon therapy who had cirrhosis, but not fibrosis, based on analysis of baseline biopsy samples. After 7 years, the cumulative incidences of HCC in treated and control patients with cirrhosis were 7.8% and 24.2%, respectively (hazard ratio [HR], 0.45; 95% confidence interval [CI], 0.24–0.83); in treated and control patients with fibrosis, incidences were 8.3% and 6.8%, respectively (HR, 1.44; 95% CI, 0.77–2.69). Treated patients with a ≥2-point decrease in the histologic activity index, based on a follow-up biopsy, had a lower incidence of HCC than those with unchanged or increased scores (2.9% vs 9.4%; P = .03). Extended analysis of the HALT-C cohort showed that long-term peginterferon therapy does not reduce the incidence of HCC among patients with advanced hepatitis C who did not achieve SVRs. Patients with cirrhosis who received peginterferon treatment had a lower risk of HCC than controls." @default.
• W2049402010 created "2016-06-24" @default.
• W2049402010 creator A5005769736 @default.
• W2049402010 creator A5013138122 @default.
• W2049402010 creator A5018098715 @default.
• W2049402010 creator A5022731052 @default.
• W2049402010 creator A5041264592 @default.
• W2049402010 creator A5043162110 @default.
• W2049402010 creator A5051411123 @default.
• W2049402010 creator A5056557259 @default.
• W2049402010 creator A5066255279 @default.
• W2049402010 creator A5070467866 @default.
• W2049402010 creator A5077140895 @default.
• W2049402010 creator A5077980742 @default.
• W2049402010 creator A5085461623 @default.
• W2049402010 creator A5086380045 @default.
• W2049402010 date "2011-03-01" @default.
• W2049402010 modified "2023-10-17" @default.
• W2049402010 title "Maintenance Peginterferon Therapy and Other Factors Associated With Hepatocellular Carcinoma in Patients With Advanced Hepatitis C" @default.
• W2049402010 cites W1944710770 @default.
• W2049402010 cites W1980033072 @default.
• W2049402010 cites W1981900811 @default.
• W2049402010 cites W1983154697 @default.
• W2049402010 cites W2009335842 @default.
• W2049402010 cites W2011791532 @default.
• W2049402010 cites W2016409892 @default.
• W2049402010 cites W2020830322 @default.
• W2049402010 cites W2027825048 @default.
• W2049402010 cites W2029879555 @default.
• W2049402010 cites W2043892107 @default.
• W2049402010 cites W2068507347 @default.
• W2049402010 cites W2075407132 @default.
• W2049402010 cites W2090439540 @default.
• W2049402010 cites W2117766751 @default.
• W2049402010 cites W2121698544 @default.
• W2049402010 cites W2130647075 @default.
• W2049402010 cites W2143558957 @default.
• W2049402010 cites W2149727669 @default.
• W2049402010 cites W2157331688 @default.
• W2049402010 cites W2157642105 @default.
• W2049402010 cites W2163083153 @default.
• W2049402010 cites W2168076454 @default.
• W2049402010 cites W2188129627 @default.
• W2049402010 cites W2419287127 @default.
• W2049402010 doi "https://doi.org/10.1053/j.gastro.2010.11.050" @default.
• W2049402010 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3057272" @default.
• W2049402010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21129375" @default.
• W2049402010 hasPublicationYear "2011" @default.
• W2049402010 type Work @default.
• W2049402010 sameAs 2049402010 @default.
• W2049402010 citedByCount "179" @default.
• W2049402010 countsByYear W20494020102012 @default.
• W2049402010 countsByYear W20494020102013 @default.
• W2049402010 countsByYear W20494020102014 @default.
• W2049402010 countsByYear W20494020102015 @default.
• W2049402010 countsByYear W20494020102016 @default.
• W2049402010 countsByYear W20494020102017 @default.
• W2049402010 countsByYear W20494020102018 @default.
• W2049402010 countsByYear W20494020102019 @default.
• W2049402010 countsByYear W20494020102020 @default.
• W2049402010 countsByYear W20494020102021 @default.
• W2049402010 countsByYear W20494020102022 @default.
• W2049402010 crossrefType "journal-article" @default.
• W2049402010 hasAuthorship W2049402010A5005769736 @default.
• W2049402010 hasAuthorship W2049402010A5013138122 @default.
• W2049402010 hasAuthorship W2049402010A5018098715 @default.
• W2049402010 hasAuthorship W2049402010A5022731052 @default.
• W2049402010 hasAuthorship W2049402010A5041264592 @default.
• W2049402010 hasAuthorship W2049402010A5043162110 @default.
• W2049402010 hasAuthorship W2049402010A5051411123 @default.
• W2049402010 hasAuthorship W2049402010A5056557259 @default.
• W2049402010 hasAuthorship W2049402010A5066255279 @default.
• W2049402010 hasAuthorship W2049402010A5070467866 @default.
• W2049402010 hasAuthorship W2049402010A5077140895 @default.
• W2049402010 hasAuthorship W2049402010A5077980742 @default.
• W2049402010 hasAuthorship W2049402010A5085461623 @default.
• W2049402010 hasAuthorship W2049402010A5086380045 @default.
• W2049402010 hasBestOaLocation W20494020101 @default.
• W2049402010 hasConcept C120665830 @default.
• W2049402010 hasConcept C121332964 @default.
• W2049402010 hasConcept C126322002 @default.
• W2049402010 hasConcept C207103383 @default.
• W2049402010 hasConcept C2775934546 @default.
• W2049402010 hasConcept C2776455275 @default.
• W2049402010 hasConcept C2777214474 @default.
• W2049402010 hasConcept C2777766500 @default.
• W2049402010 hasConcept C2778019345 @default.
• W2049402010 hasConcept C44249647 @default.
• W2049402010 hasConcept C61511704 @default.
• W2049402010 hasConcept C71924100 @default.
• W2049402010 hasConcept C72563966 @default.
• W2049402010 hasConcept C88879693 @default.
• W2049402010 hasConcept C90924648 @default.
• W2049402010 hasConceptScore W2049402010C120665830 @default.
• W2049402010 hasConceptScore W2049402010C121332964 @default.
• W2049402010 hasConceptScore W2049402010C126322002 @default.
• W2049402010 hasConceptScore W2049402010C207103383 @default.
• W2049402010 hasConceptScore W2049402010C2775934546 @default.

• next